Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126878081 | 12687808 | 1 | I | 20160812 | 20160826 | 20160826 | EXP | TN-MLMSERVICE-20160808-0383873-1 | TN-ACCORD-043386 | ACCORD | MELEK K, SONIA H, WALID B, LEILA N, RIM K, ABDELFATTEH Z. AUTOIMMUNE HEMOLYTIC ANEMIA REVEALING CLASSICAL HODGKIN LYMPHOMA: TWO CASE REPORTS AND LITERATURE REVIEW. PHILLIPPINE JOURNAL OF INTERNAL MEDICINE. 2016; 54(2) | 50.00 | YR | M | Y | 0.00000 | 20160826 | MD | TN | TN |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126878081 | 12687808 | 1 | PS | ETOPOSIDE. | ETOPOSIDE | 1 | ON DAY 1 AND DAY 8 (8 CYCLES) | 74513 | 100 | MG/M**2 | |||||||||
| 126878081 | 12687808 | 2 | SS | DOXORUBICIN/DOXORUBICIN HYDROCHLORIDE | DOXORUBICIN HYDROCHLORIDE | 1 | ON DAY 1 AND DAY 8 (8 CYCLES) | 0 | 35 | MG/M**2 | |||||||||
| 126878081 | 12687808 | 3 | SS | CYCLOPHOSPHAMIDE/CYCLOPHOSPHAMIDE MONOHYDRATE | CYCLOPHOSPHAMIDE | 1 | ON DAY 1 AND DAY 8 (8 CYCLES) | 0 | 1200 | MG/M**2 | |||||||||
| 126878081 | 12687808 | 4 | SS | VINCRISTINE | VINCRISTINE | 1 | ON DAY 1 AND DAY 8 (8 CYCLES) | 0 | 1.4 | MG/M**2 | |||||||||
| 126878081 | 12687808 | 5 | SS | PROCARBAZINE/PROCARBAZINE HYDROCHLORIDE | PROCARBAZINE HYDROCHLORIDE | 1 | ON DAY 1 AND DAY 8 (8 CYCLES) | 0 | 100 | MG | |||||||||
| 126878081 | 12687808 | 6 | SS | PREDNISONE/PREDNISONE ACETATE | PREDNISONE ACETATE | 1 | ON DAY 1 AND DAY 8 (8 CYCLES) | 0 | 40 | MG/M**2 | |||||||||
| 126878081 | 12687808 | 7 | SS | BLEOMYCIN | BLEOMYCIN SULFATE | 1 | 4 CYCLES, ALSO RECEIVED AT 10 MG/M^2 ON DAY 1 AND 8 FOR SAME INDICATION (BEACOPP CHEMOTHERAPY) | 0 | 15 | MG | |||||||||
| 126878081 | 12687808 | 8 | SS | VINBLASTINE/VINBLASTINE SULFATE | VINBLASTINEVINBLASTINE SULFATE | 1 | 4 CYCLES | 0 | 10 | MG | |||||||||
| 126878081 | 12687808 | 9 | SS | DACARBAZINE/DACARBAZINE CITRATE | DACARBAZINE CITRATE | 1 | 4 CYCLES | 0 | 375 | MG/M**2 | |||||||||
| 126878081 | 12687808 | 10 | C | PREDNISONE/PREDNISONE ACETATE | PREDNISONE ACETATE | 1 | HIGH DOSES | 0 | 1 | MG/KG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126878081 | 12687808 | 1 | Hodgkin's disease mixed cellularity stage III |
| 126878081 | 12687808 | 2 | Hodgkin's disease mixed cellularity stage III |
| 126878081 | 12687808 | 3 | Hodgkin's disease mixed cellularity stage III |
| 126878081 | 12687808 | 4 | Hodgkin's disease mixed cellularity stage III |
| 126878081 | 12687808 | 5 | Hodgkin's disease mixed cellularity stage III |
| 126878081 | 12687808 | 6 | Hodgkin's disease mixed cellularity stage III |
| 126878081 | 12687808 | 7 | Hodgkin's disease mixed cellularity stage III |
| 126878081 | 12687808 | 8 | Hodgkin's disease mixed cellularity stage III |
| 126878081 | 12687808 | 9 | Hodgkin's disease mixed cellularity stage III |
| 126878081 | 12687808 | 10 | Hodgkin's disease mixed cellularity stage III |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126878081 | 12687808 | OT |
| 126878081 | 12687808 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126878081 | 12687808 | Drug ineffective | |
| 126878081 | 12687808 | Sepsis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |